← Back to patent-cliff list
Enrupatinib
Tier C — Watch / tradeEnrupatinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CSF1R
Indications (approved)：Alzheimer's disease, Amyotrophic lateral sclerosis, Tenosynovial giant cell tumour
Regional status
US
Phase I
2019-12-27
EU
-
China
Phase I
2023-03-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Enrupatinib?
Approved indications include: Alzheimer's disease, Amyotrophic lateral sclerosis, Tenosynovial giant cell tumour.
When does the Enrupatinib patent expire?
No public expiry year is available for Enrupatinib yet; this page updates once verified.
How do I get a quote for Enrupatinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01